| Gender Preference | None |
| Age Group | 0 - 29 years |
| Research Start Date | December 17, 2011 |
| Research End Date | December 17, 2021 |
| Principal Investigator | Ayman El-Sheikh, MD |
| Description | ARST0921: A randomized phase II trial of bevacizumab (IND 7921, Avastin) and temsirolimus (IND61010, torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma
Participants in this study have Rhabdomyosarcoma (RMS). Rhabdomyosarcoma occurs in soft tissues like the muscles and it can occur in many places in the body. This cancer is recurrent or refractory. Recurrent means that the cancer has come back after treatment. Refractory means that the cancer has not responded to treatment. The purpose of this study is to test 2 experimental drug combinations in the hope of finding a new therapy for fighting this particular cancer. The 2 drug combinations are:
1) vinorelbine and cyclophosphamide with bevacizumab
2) vinorelbine and cyclophosphamide with temsirolimus
Approximately 4 people will take part in this study conducted by investigators at the University of Iowa. The total number of people enrolled on this study nationwide is expected to be 100 |
| Contact Info | Julie de la Garza, 319-356-3749 |
| Keywords | span itemProp='description'>bevacizumab ; cancer ; Children ; cyclophosphamide ; pediatric ; phase 2 ; phase II ; recurrent ; refractory ; rhabdomyosarcoma (RMS) ; tannous ; temsirolimus ; vinorelbine ; |